Exparel sales up 22.4% after CMS offers coverage — 3 quick insights

For the first quarter, Pacira BioSciences reported record sales of Exparel, a non-opioid pain management drug that became eligible for separate Medicare reimbursement in ASCs as of Jan. 1.

Advertisement

Three quick insights:

1. Net sales of Exparel reached $90.6 million in the first quarter of 2019, a year-over-year increase of 22.4 percent.

2. ASCs and oral surgery centers were the key drivers of Exparel utilization.

3. Pacira’s total first-quarter revenues were $91.3 million, up from $74.6 million in the first quarter of 2018.

More articles on anesthesia:
SouthEast Eye Specialists adds Drs. JD Bonner, Will Whitmire — 3 insights
Happy 25th birthday Arizona Institute of Medicine and Surgery — 4 insights
Meet Chesapeake Urology’s newest specialist — 3 highlights

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Anesthesia

  • Anesthesiologist pay keeps climbing even as the reimbursement underneath it keeps shrinking, which is a gap ASCs are increasingly bridging…

  • The Morgantown-based West Virginia University School of Nursing is increasing its Doctor of Nursing Practice Nurse Anesthetist program from 15…

Advertisement

Comments are closed.